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Abstract
Idiopathic pulmonary fibrosis (IPF) is known as one of the most severe lung 
conditions and the worst form of interstitial lung disease (ILD). There is a continu-
ing concern about clinical research to identify new therapies that influence the 
quality of life in patients diagnosed with this chronic progressive pulmonary disease, 
with an average survival of 3–5 years. Although in recent years great progress has 
been made to slow down the functional decline of the disease with new antifibrotic 
therapies, it has failed to alter the prognosis and survival of IPF patients. Clinical tri-
als and recent ATS/ERS guidelines have brought at least moderate and low levels of 
evidence for increased effort tolerance, decreased symptoms, and improved quality 
of life following participation in lung rehabilitation programs for ILD patients and in 
particular those with IPF. Pulmonary rehabilitation has been shown to be a standard 
of care for COPD patients, but their personalized application to patients with IPF has 
had positive short-term results, becoming a safe alternative to non-pharmacological 
treatment. The chapter includes the general objectives of rehabilitation programs, 
their type and structure, ways of complex assessment of patients before and after a 
training exercise, types of exercises, and short- and long-term results.
Keywords: idiopathic pulmonary fibrosis (IPF), pulmonary rehabilitation  
program (PRP), physical activity, exercise training, quality of life
1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic disease that affects exclusively 
the lung, with an unknown etiology and a fast-progressive irreversible evolution, 
therefore disabling the adult. For most of the patients, the average survival is 
approximately 3–5 years from diagnosis [1, 2]. With an unpredictable but progres-
sive evolution (slower, stable, or accelerated decline from patient to patient), the 
disease is characterized by a chronic presence of symptoms, specifically the exer-
tional dyspnea, low tolerance to effort, and the deterioration of the quality of life 
[1–4]. The diagnosis of the disease is often delayed and not reported until advanced 
stages [5]. A hope to halt the progression of the disease occurred with the dem-
onstration of the reduction in the functional decline of the new pharmacological 
agents, pirfenidone and nintedanib, without claiming to cure the disease [1–5]. IPF 
remains a life-threatening illness in which the patient is fighting for survival as long 
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as possible, striving to cope with the symptoms and the noticeable fatigue. Given 
that this is a fatal disease, some of the needs identified in patients with IPF and their 
families are easy access to information and IPF specialists, the existence of more 
treatment methods, emotional support, and access to end-of-life care [3].
The indication of pulmonary rehabilitation (PR) for patients with IPF came 
from the positive results stemming from the exercise training program (ETP) in 
COPD. Thus, numerous clinical studies performed on patients with IPF proved that 
their health and wellness could be improved, at least for short periods, through ETP 
which are personalized and supervised by specialists [2].
Pulmonary rehabilitation program (PRP) is an evidence-based recommenda-
tion for the non-pharmacological treatment of patients with chronic pulmonary 
diseases, especially for COPD, but also for interstitial lung diseases [1, 4]. PRP must 
be included in the integrative treatment of IPF, taking into consideration the sever-
ity of the disease, high mortality during exacerbations, a modest response to new 
drugs, and accelerated deterioration of lung function.
2.  The indication of pulmonary rehabilitation starting from 
pathophysiology in IPF
The usual interstitial pneumonia (UIP) pattern (fibrosis with collagen and 
matrix deposition, the presence of fibroblastic foci and alveolar collapse, pulmo-
nary heterogeneous architectural distortion and honeycombing presence) deter-
mines the main pathophysiological changes in IPF: loss of lung volume, decreased 
lung compliance, abnormal pulmonary gas exchange with oxygen diffusion limita-
tion, low mixed venous oxygen content, circulatory impairments, and alveolar 
ventilation/perfusion (V′A/Q′) mismatching [6, 7].
Pulmonary function tests reveal restrictive pulmonary dysfunction, indirect 
signs of increased elastic recoil, and decrease in diffusion capacity for carbon mon-
oxide (DLCO). Pulse oximetry and arterial blood gases reveal hypoxemia initially 
only during exercise and, in advanced cases, as well during resting [2, 7]. Patients 
with IPF have reduced maximal or peak oxygen uptake (V’O2peak), peak work rate, 
and submaximal exercise endurance [7].
The progressive installation of morphophysiopathological changes is reflected 
in the clinical symptoms of patients. The exertional dyspnea is the first and most 
important symptom of IPF patients. The more advanced the disease, the more 
severe the dyspnea is. The patients tend to be less physically active and more 
depressed [8]. The level of dyspnea is strongly correlated with the exercise capacity, 
the quality of life, and mortality [1, 8, 9]. Other associated symptoms are fatigue, 
dry cough, chest discomfort, and leg pain. These symptoms are mild or inconsistent 
at the beginning of the disease, but they get worse over time and lead to an impair-
ment of daily activities [10]. Symptomology and physical inactivity are directly 
related to depression, quality of life (QoL), and increased mortality [10, 11].
Consequently, the most important mechanisms that limit effort capacity and 
change the IPF patient’s lifestyle, into a sedentary one, are inefficient breathing 
mechanics, abnormal pulmonary gas exchange, circulatory impairment, and 
exercise-induced hypoxemia [1, 7, 12, 13]. In time, progressive exercise-induced 
hypoxemia leads to respiratory and skeletal muscle dysfunction [1, 7]. Non-
pharmacological interventions must take into account these mechanisms and create 
programs that seek to influence the patients’ outcomes positively. PR is a safe and 
effective non-pharmacological treatment [14].
The official ERS/ARS statement define pulmonary rehabilitation as “Pulmonary 
rehabilitation is a comprehensive intervention based on a thorough patient 
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assessment followed by patient tailored therapies that include, but are not limited 
to, exercise training, education, and behavior change, designed to improve the 
physical and psychological condition of people with chronic respiratory disease and 
to promote the long-term adherence to health-enhancing behaviors” [11].
PR decreases dyspnea, improves exercise capacity, and helps to cope with 
functional activities of daily life in IPF patients, even though the significance of 
these benefits is smaller and lasts for less time than in other chronic lung disease like 
COPD [15–20].
3. General objectives of pulmonary rehabilitation in IPF
• Decreasing symptoms, especially dyspnea
• Increasing effort capacity
• Enhancing the quality of life, health, and wellness
• Improving muscle strength and endurance
• Maintaining joint mobility
• Increasing tolerance to physical activity with the improved cardiometabolic 
and respiratory profile
• Improving well-being and cognitive functions
• Decreasing depression and anxiety
• Offer social and psychological support with the possibility of occupational and 
group therapy
• Promoting pro-healthy behaviors, with decreasing effort deconditioning
• Self-management of the disease [20–22]
The adaptation of pulmonary rehabilitation programs for IPF started from those 
applied to patients with COPD. It is advised to take into account the pathophysiol-
ogy mechanisms particular to IPF and the clinical particularities of these patients. 
Patients have a respiratory pattern of frequent, superficial, and rapid breaths that 
worsen during exercise [7, 17, 18]. The frequent association of pulmonary hyperten-
sion (PH) aggravates the symptoms [1, 4]. An explanation for the positive results 
of PRP could be that repetitive ventilator stimulus during physical training sessions 
increases chest expansion and secondary pleural elasticity and pulmonary compli-
ance while also improving V’A/Q‘ mismatch, increasing V’O2peak [13, 23]. Also, deep 
breathing exercises with stretching and the training of respiratory muscles, includ-
ing the diaphragm, can help to reduce dyspnea [20, 23, 24].
4. Assessment of IPF patients before and after PRP
Before entering into a PRP, patients with IPF need to be assessed by the multidis-
ciplinary team regarding clinical and functional status, imaging, effort tolerance, 
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quality of life, physical activities of daily living (PADL), the presence of comorbidi-
ties, needs, and expectations from the pharmacological treatment. The evaluation of 
comorbidities such as coronary arterial disease, systemic and pulmonary hyperten-
sion, right and left ventricle dysfunction, and arrhythmias during exercise is critical. 
The additional impairment of the cardiovascular system decreases the effort capacity 
and worsens dyspnea and prognosis of patients [1, 2, 25]. This complex assessment 
also has the role in determining the type, intensity, and results of the PRP.
4.1 Symptoms assessment
Dyspnea is the most significant and disabling symptom for IPF patients. It can 
be objectively identified before, in the end, and at any time within PRP and can 
modulate the intensity of exercise. In studies targeting PR in IPF, dyspnea is quanti-
fied using one of the following scales:
4.1.1 Modified Medical Research Council (MMRC)
The Modified Medical Research Council (MMRC) scale is a well-known tool which 
assesses the dyspnea based on 5 degrees that are reported by the patient depending 
on his physical activity tolerance. It seems that dyspnea severity correlates with lung 
function parameters and Saint George Respiratory Questionnaire (SGRQ). The patient 
identifies the number that best matches his/her shortness of breath [26–28]. The 
standardized mean difference (SMD) for change in dyspnea in favor of exercise train-
ing (ET) is considered to be −0.66 (95% CI=1.05-0.28) [15]. MMRC dyspnea scales 
reflect the severity of the limitation of daily activity, pulmonary function, and quality 
of life and correlate with mortality. It can replace, where it is not possible to asses, the 
peripheral muscle strength, functional exercise capacity, and ADL performance [29].
4.1.2  University of California, San Diego Shortness of Breath Questionnaire 
(UCSD SOB)
The University of California, San Diego Shortness of Breath Questionnaire (UCSD 
SOB) uses a 24 questions questionnaire about the level of dyspnea during daily 
activities [30]. Five points represent a significant mean difference [31]. Dyspnea 
measured by UCSD SOB showed the strongest correlations with 6MWD [32].
4.1.3 Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI)
The Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) assesses on a 
5-degree scale (from 0 to 4), the daily dyspnea level in response to three categories 
of questions on functional impairment, the magnitude of task, and the magnitude 
of effort [26, 33, 34]. TDI records the changes from the initial value, the total score 
varying between −9 (worsening) and +9 (improvement). The significant minimal 
difference between TDI is 1 point [33, 34].
4.1.4 Modified Borg Scale (MBS)
The Modified Borg Scale (MBS) has 10 points (from 0 to 10), where participants 
choose descriptive terms that best suit their current state (0 = no dyspnea, 5 = moderate 
dyspnea, 10 = very severe dyspnea). It is used before and after performing a submaxi-
mal effort test such as 6MWT. The standardized significant mean difference (SMD) 
for change is 1 point [31]. During exercise training sessions in the PRP, the Borg scale is 
used as an essential tool to recommend workload [35].
5The Role of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis
DOI: http://dx.doi.org/10.5772/intechopen.84283
It was shown that there are correlations between clinical dyspnea rating and 
exercise capacity, exercised gas exchange and exercise capacity, and SGRQ in 
patients with IPF [26, 29, 36].
4.2 Pulmonary function tests
Pulmonary function tests, including forced vital capacity (FVC), total lung 
capacity (TLC), maximal voluntary ventilation (FEV1 x 35), and diffusion capac-
ity for carbon monoxide (DLCO), are important for stratifying the severity of the 
patient’s condition, but generally, PRP does not significantly influence the results 
of these tests [20]. The severity of dysfunction may guide the type and intensity 
of physical exercise and may be a warning about the risk of adverse effects (severe 
hypoxemia, hypotension, arrhythmias, etc.)
4.3 Standardized effort tests
Standardized effort tests are important for choosing the intensity of training 
programs.
4.3.1 The 6-minute walking test (6MWT)
The 6-minute walking test (6MWT) is a simple and safe tool used for IPF patients, 
where the subject moves in his rhythm [37]. It is performed according to ATS guide-
lines in a 30-m corridor [38]. 20–30 min of rest is recommended before and after the 
6MWD test. The blood pressure, heart rate, respiratory frequency, oxygen satura-
tion (SpO2), the severity of dyspnea, and fatigue are assessed by the modified Borg 
scale [38, 39]. SpO2 is recorded in the sitting position. It is recommended that the 
6MWD test be performed with a SpO2 Holter, to record the length of the desatura-
tion and the lowest value of oxygen [40]. It is always necessary to take into consider-
ation the contraindications of walking tests and also the indications of interruption 
of the test. An important cessation criterion is a desaturation below 85% or tachycar-
dia [80% of the theoretical maximum heart rate ( 220−age )], a situation easily met 
in IPF patients [1, 41]. The distance covered by the patient in 6 minutes is compared 
with the predicted value estimated by the formulas (women: 493 + (2.2 × height 
(cm)) − (0.93 × G (kg)) − 5.3 × age (years) and for the male + 17 m). The lower limit 
of normal 6MWD is the theoretical distance minus 100 m [42–44]. The 6-minute 
walk test distance (6MWD) does not correlate with sex, age, body mass index, and 
other medical comorbidities, but it is an independent predictor of survival rate, bet-
ter than FVC and DLCO [37]. The 12-minute walk test is less used for IPF patients 
because it requires greater effort.
The minimal clinical important significant difference (MCID) for 6MWD varies 
with the author, but a change of approximately 30 m is considered to be significant 
in IPF patients [32, 41, 44, 45].
4.3.2 Cardiopulmonary exercise tests
Cardiopulmonary exercise tests, when available, provide details on the mechanisms 
of effort intolerance. Measures of the anaerobic threshold, peak oxygen consump-
tion (V′O2peak), and peak work rate (WR) are essential for determining the intensity 
of PRP and for assessing the benefits in dynamics. The SpO2, blood pressure, and 
12-lead electrocardiogram are also recorded during these tests [46]. Cardiopulmonary 
stress tests are the gold standard for assessing the effort intolerance due to either 
lung, cardiac, or musculoskeletal pathologies. It is performed with a cycle ergometer 
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or treadmill, but there is also a portable metabolic device. Cycle ergometry is the 
preferred method of being safer, with few movement artifacts, allowing a constant 
increase in workload, and is slightly influenced by weight [46–48]. Treadmill testing 
involves a kind of effort more common to patient’s daily activities (walking and run-
ning) and can train more muscle mass. Therefore, the V′O2peak is 5–10% higher than in 
cyclo-ergometry. Effort tests have a role in selecting patients for PRP and establishing 
rehabilitation design protocols, as well as evaluating outcomes [48].
In patients with advanced IPF, it is not always possible to perform cyclo-ergome-
try. Volitional fatigue or increased oxygen desaturation (SpO2 < 80%) is quickly 
reached, and dizziness or mental confusion may also occur within 10–12 min of 
effort [48]. The incremental exercise testing shows decreased aerobic capacity 
(V′O2peak ~ 62% from predicted) and reduced maximal achievable workload in 
ILD. Other changes in IPF patients such as inefficient ventilation, desaturation, gas 
exchange abnormalities, circulator, and skeletal muscle dysfunction are reported 
[2]. These changes provoke a downward spiral of hypoxia, limited exercise capacity, 
deconditioning, shallow breathing pattern, and pulmonary hypertension [48].
4.4 Doppler-echocardiographic assessment
Doppler-echocardiographic assessment of pulmonary artery systolic pressure 
should be assessed because a significant percentage of the IPF patients develop 
PH from early stages of the disease [10, 49]. It represents an important prognostic 
parameter [10, 49]. It usually replaces right heart catheterization, echocardiogra-
phy being a noninvasive and widely available tool for screening PH. A substantial 
desaturation during exercise or a disproportionate exercise limitation related to the 
degree of lung restriction will increase the suspicion of PH [7, 10].
4.5  Chest high-resolution computed tomography (HRCT) and  
lung ultrasound
HRCT is the essential method to diagnose IPF. If the HRCT shows a pattern of 
usual interstitial pneumonia (UIP), this being the most characteristic to IPF, then 
its presence avoids invasive procedure such as lung biopsy. In the last few years, 
radiation-free techniques, such as the lung ultrasound, appear to be very sensitive 
in detecting fibrotic change or monitoring disease progression [50]. Imaging on 
HRCT is important and significant before a PRP, but its rehabilitation benefits are 
not assessed according to the initial findings.
4.6 Physical activity of daily living (PADL)
Physical activity of daily living (PADL) has a major impact on the quality of life 
and well-being of IPF patients and needs to be evaluated. PADL refers to volunteer 
movements that the patient performs at home, during professional or recreational 
activities that are energy-consuming. There is an inversely proportional relationship 
between PADL and sedentariness, reduced autonomy, disability, risk of hospital-
ization, and death [51]. Besides, the disease severity (dyspnea levels, SpO2 < 88%, 
DLCO < 40%, 6MWD, the extent of honeycombing on computed tomography, level 
of PH) was associated with lower physical activity among patients’ stable IPF [52].
4.6.1 PADL assessment
PADL assessment is performed either by direct observation (time and staff 
consuming because it is individually applied), energy expenditure (for research 
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calorimetry), questionnaires, and other devices with motion sensors (detect move-
ment and quantify PADL: pedometers, accelerometers, or physical activity monitors). 
The questionnaires are subjective methods of evaluating the effects of the symptoms 
on the patient’s daily activities and quality of life, and they are instruments that are 
used in evaluating PRP [53]. Achieving progress through training programs can 
motivate the patient to pursue an active lifestyle for as long as possible. Pedometers 
measure only the distance covered daily (10,000 steps/day for a healthy lifestyle in 
the general population), but the effort intensity is better quantified by accelerometers 
[54]. These are preferred in sedentary or disabled patients, being more sensitive to the 
detection and description of movements. Daily activity can be quantified using  
the activity monitor for at least seven consecutive days from awakening to bed [2]. 
The intensity of physical activity is evaluated on a scale of 1–5, depending on the 
energy expenditure, expressed in the metabolic equivalent task (METS) [55].
4.6.2 The questionnaires used in PADL evaluation
The questionnaires used in PADL evaluation for IPF are easy to apply, cheap, 
self-administered, validated (internal consistency and test-retest reliability) and 
correlate with the estimated energy consumption by the methods mentioned above. 
The most commonly used questionnaires in clinical studies, which are extrapolated 
to IPF patients, are as follows:
4.6.2.1  Self-report 7-day short form International Physical Activity Questionnaire 
(IPAQ )
Self-report 7-day short form International Physical Activity Questionnaire (IPAQ ) 
[2, 56] consists of nine items which evaluate the level of physical activity that is 
quantified in METS for the effort intensity: vigorous (8 METS), moderate  
(4 METS), walking (3.3 METS), and sitting times. The total score is the sum of all 
types of activities (the number of minutes spent/day) multiplied by the level of 
energy (MET) and multiplied by the amount of time spent/week [(MET)-min/week] 
[55]. An active patient is considered to perform 600 METS-min/week (150 min/
week × 4METS moderate intensity activity) [54, 57]. IPAQ ≤ 417 (MET-min/week) 
∆SpO2 < 10 (%) represents the cutoff which predicts mortality in patients with IPF 
[2]. However, there were differences between the self-reported patient score on the 
questionnaire and the accelerometer’s results, depending on sex, age, education level, 
and body mass index (BMI). There is also a short form for this IPAQ [58].
4.6.2.2 Barthel index (BI)
Barthel index (BI) is based on basic physical activities for self-grooming, such as 
feeding, toilet use, bladder and bowel control, walking, dressing, bathing, brushing, 
or ascending and descending stairs. The total scores vary between 0 and 70; higher 
scores are associated with more active subjects. A change in the BI score after 1 
month of ET4 was arbitrarily classified as mild (a decrease of <10 points), moderate 
(10–15 points), or severe (>15 points) [59]. This index reflects the independence 
levels in PADL in IPF patients.
4.6.2.3 Baecke questionnaire
In Baecke questionnaire, the score reflects the level of energy consumed perform-
ing professional activities, sports, and entertainment and is also adapted for the 
elderly, obese, and Parkinson’s disease or cardiovascular patients [60].
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4.6.2.4  Stanford Seven-Day Physical Activity and Stanford Usual Activity 
questionnaires
Stanford Seven-Day Physical Activity and Stanford Usual Activity questionnaires are 
applied during an interview. The first one relates to the time spent doing physical 
activities and sleeping for the past 7 days. The second focuses on moderate and 
intense activities in the last 3 months [61].
The PADL level is positively influenced by supervised PRP that lasts at least 
7–8 weeks.
4.7 The quality of life questionnaire
The quality of life questionnaire has been developed and validated extrapolat-
ing those applied to COPD patients, given the lack of a specific disease-specific 
questionnaire for IPF [56].
4.7.1 St. George Respiratory Questionnaire (SGRQ )
St. George Respiratory Questionnaire and St. George Respiratory Questionnaire 
IPF-specific version (SGRQ-I) consist of 50 items referring to three categories: 
symptoms (8 items), activity (16 items), and impact (26 items) [36, 62, 63]. The 
total score varies from 0 to 100 points. Higher scores reveal a poorer health-related 
quality of life. SGRQ-I is reliable and comparable to the original SGRQ [64]. 
The SGRQ score was significantly correlated with FVC, FEV1 (%), 6MWD, and 
MRC. On the other hand, it did not show a significant correlation with DLCO or the 
level of desaturation at 6MWD, compared with CAT questionnaire [64].
4.7.2 Medical Outcomes Short-Form 36 (SF-36)
Medical Outcomes Short-Form 36 (SF-36) is a generic health-related quality of life 
questionnaire. It consists of eight multidimension items as general health, vitalities, 
physical functioning, physical role/problems, body pain, emotional roles/problems, 
social functioning, and mental health. Each of the dimensions is scored from 0 to 
100. Higher scores indicate a better health-related quality of life [65].
4.7.3 Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) can be applied in any dis-
abling chronic disease which leads to impairment of the psychic/emotional status of 
patients [66].
4.7.4 The Chronic Respiratory Disease Questionnaire (CRDQ )
The Chronic Respiratory Disease Questionnaire (CRDQ ) refers to dyspnea, fatiga-
bility, emotional impact, and self-control [67].
4.7.5 COPD assessment test (CAT)
COPD assessment test (CAT) was compared with other instruments applied to 
patients with IPF showing good psychometric properties among ILD patients. It is 
a self-administered questionnaire with eight items, each scored on a scale from 1 to 
5. There is a strong correlation between the CAT score and SGRQ score, indicating 
that it can be used for health-related quality of life assessment among patients with 
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IPF. Furthermore, CAT showed higher correlations with the physiological param-
eters than the SGRQ [67].
4.7.6 Tool to Assess Quality of Life in Idiopathic Fibrosis (ATAQ-IPF)
The Tool to Assess Quality of Life in Idiopathic Fibrosis (ATAQ-IPF) is an 
extensive, 74 items, a disease-specific instrument which measures the symptoms 
adequately, sleep, emotions, relationships, therapies, finances, and many others. 
The score correlates with disease severity, but future studies are needed [8].
4.7.7 King’s Brief Interstitial Lung Disease (K-BILD)
The King’s Brief Interstitial Lung Disease (K-BILD) questionnaire is a validated 
and responsive questionnaire for longitudinal assessment of ILD patients’ quality of 
life. A score change of 5 units is significant [68].
4.8 Muscle strength assessment
In muscle strength assessment, types of muscular impairment refer to mass 
(of different anatomical sites: biceps, triceps, etc.), strength, endurance, and 
performance [69]. Peripheral muscle force measurement may be important in 
PRP for understanding the impact of the disease on muscle mass, identifying 
patients at risk for physical impairment, and identifying those who can benefit 
from the prescription of an individualized resistance training program. Peripheral 
muscular dysfunction is a consequence of sedentary lifestyle, adopted by patients 
to avoid the symptoms and systemic effects of the disease (inflammation, 
hypoxemia, nutritional deficiency, corticosteroid side effects, electrolyte imbal-
ances). Commonly, quadriceps muscle dysfunction is used for the assessment of 
peripheral muscle strength. The tests that are used may be volitional (volitional 
techniques: identification of the maximum weight that the patient can lift, manual 
muscle testing with MRC scale, or by dynamometers: handheld and computer-
ized) or non-volitional (electrical stimulation of involuntary muscle contraction). 
The quadriceps maximal isometric voluntary contraction (QMVC) or predictive 
formulas (different equations for predicting quadriceps muscle strength) are 
described in literature, especially in studies on patients with COPD [70–72]. It is 
considered that patients have quadriceps muscle weakness if the value is <80% of 
predicted [73]. Knee extensor and elbow flexor strength could be measured with 
handheld dynamometer [69].
5.  Correlation between exercise tolerance, daily physical activity, and 
survival rate
a. 6MWD is an independent and discriminating predictor of mortality among 
patients with IPF, more accurate than FVC or DLCO [74, 75]:
• Basal value <250 m correlates with twofold increase in mortality, and if it is 
less than 207 m, patients have a more than fourfold greater mortality rate.
• A decrease of SpO2 < 88% during 6MWT is marker for increased mortality.
• A decrease in the walking distance within 6 months, greater than 50 m, 
would increase the mortality rate by three times.
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• A delayed heart rate return in 1 minute after the end of the 6MWD test and a 
variation <13 beats/min are strongly correlated with increased mortality.
b. Daily life physical activity level [76–78]:
• IPF patients are highly sedentary, having a daily physical activity level which 
is 35% lower than healthy sedentary controls.
• A value under 3.287 steps/day on accelerometers was associated with a 
poorer prognosis and three times higher risk for death for IPF patients.
• Peripheral muscle dysfunction related with a decrease of the physical activity 
level of daily life and exercise limitation is associated with reduced survival.
6. Types of pulmonary rehabilitation programs
PRP for IPF patients include several types of exercises, such as aerobic, resis-
tance, flexibility, balance training, and respiration technique. Their selection is 
based on the everyday lifestyle of each patient, preferences, disease severity, and 
the advantages of where the PRP will take place:
• “Inpatient” rehabilitation centers are a more appropriate method for the 
supervised exercise programs taking into account the symptoms and the risk of 
severe effort desaturation that may occur. The advantage is that during exercise 
sessions, patients are monitored for blood pressure, heart rate, SpO2, and symp-
toms, and the urgent treatment is available in case of complications [79, 80].
• “Outpatient”-based programs take place in the patient’s home under the 
assistance of a healthcare professional with expertise in exercise training.
• Home-based rehabilitation programs are an alternative to in-/outpatient pro-
grams. They are easy to perform, practical, cheap, and equally as effective, 
but unfortunately have a lower adherence rate and less improvements, so it is 
necessary to be supervised by phone calls [12, 78, 79, 81].
• Combined programs start in a specialized structure and continues at home 
after the patients are familiar with the type and intensity of exercise [83].
PRP includes physical training, patient education, and nutritional and psychological 
support [11]. Regardless of the type of PRP, it is beneficial to start it as soon as possible. 
We will keep in mind that the intensity of rehabilitation depends on the severity of 
functional impairment and is personalized to each patient. The physical therapist starts 
from breath retraining and relaxing postures which increase chest expansion and relax 
the inspiratory muscles (Jacobson, Schultz technique). They reinforce proper breathing 
patterns (diaphragm) and include exercises that tonify respiratory and skeletal muscle 
(endurance and resistance) in order to increase patients’ exercise capacity [2].
7. Types of exercises
The main objective of these training programs is teaching patients how to per-
form a series of structured and repetitive exercises that improve or maintain their 
physical fitness and decrease the respiratory discomfort [82].
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Educating patients about pursuing an active lifestyle even in the presence of IPF 
should be based on information about the types of exercises that can be performed, 
the regularity and duration of each session, and general instructions on how and 
what to follow through the program. During the follow-up with their patients, the 
doctor may be confronted with various questions, doubts, and anxiety from the 
patients. In the early stages of the disease, when the symptoms are not disabling, 
the patient’s motivation to follow a PRP is low. In advanced stages, the motivation 
is stronger because dyspnea limits exercise capacity and daily activities. According 
to several studies, the PRP with greatest benefits have 6–12 weeks programs, with 
2–3 sessions per week of 30 minutes duration. The exercise intensity is determined 
by patients’ walking speed on 6MWD (starting at 70–80%), or by the maximum 
workload on cycle ergometer test (50–60% or more of peak WR on CPET for 
cycling), maximum heart rate (up to 80%), or on the intensity of symptoms on the 
Borg scale (to reach a score above 5–7). The effort intensity can also be calculated 
from an average heart rate ± 5 beats, obtained in the last 3 minutes of the effort test 
[2, 21, 33, 84].
A comprehensive training program should include several types of exercises: 
breathing and balance exercises, aerobic, endurance, and flexibility (stretching)  
[2, 12, 20, 33, 84].
For increasing the endurance to effort, aerobic exercises can be used to train 
different muscle groups, depending on the patients’ preferences and physical 
resources. Aerobic exercises can include walking, stair climbing, treadmill walking, 
leg cycling, semi-recumbent cycling, or step climbing on an ergometer adapted for 
lower limbs [16]. Resistance training refers to the increase in muscle strength and 
can be achieved by performing repeated exercises for upper and lower limbs, arm 
raising, knee-extension, sit-to-stand, and strength training using elastic bands. 
In these types of exercises, the muscles work against an external force applied by 
a device from the physiotherapy room or against their own body weight. They can 
also use weights. These exercises are grouped in 2–4 sets, with 10–15 repetitions, 
followed by breaks of 45–60 s. Each set of exercises targets specific muscle groups 
[85]. These exercises are recommended due to the fact that IPF patients have 
reduced muscle mass, strength, and endurance, compared with healthy subjects. 
They develop atrophy and muscle weakness, especially in lower limbs [86, 87]. 
Stretching exercises are activities designed to maintain or increase joint mobility 
and muscle relaxation. Strength training targets major muscle groups of the upper 
and lower body. There is a wide range of exercises that could be applied by physio-
therapist [88]:
• Shoulder wheel
• Multiple movements of shoulder by changing his position as abduction, 
externally rotates the shoulder, flexion, and extension
• Sitting or standing biceps curls
• Mid-back rowing
• Shoulder flexion or extension
• Sitting or standing chest presses and triceps extensions
• Lower body exercises: standing hip abduction and extension
• Seated knee flexion and extension
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• Internal and external rotations of the abducted shoulder with the elbow  
flexed 90 degrees
• Wall push-ups
• Chair squat
• Dumbbells shoulder press
• Dumbbells biceps curls
• Dumbbells arm extension
• Abdominal curl-ups
• Seated single leg hamstring stretch
• Standing quadriceps stretch
• Chest stretch
• Overhead reach stretch and wall cat stretch
For strength training there are three types of therapeutic bands that can be used: 
yellow, followed by red, and then green.
Respiratory muscle training or breathing exercises are extremely important, 
especially for patients with advanced disease, because they focus on diaphragm 
training, by teaching patients abdominal breathing techniques [79, 89].
There are no strictly standardized protocols for the PRP, allowing an experi-
enced physiotherapist to tailor the patient’s training structure in order to maximize 
the benefits.
The structure of a rehabilitation program should be seen as a multistage process:
• Firstly, the patient learns different types of exercise and different techniques, 
which can be divided into four categories (aerobic, endurance, flexibility, 
and breathing). Their intensity should be adapted to the severity of patient’s 
pulmonary impairment, typically 50–60% of the work peak rate for aerobic 
exercise and 70–80% of the walking speed in 6MWT for endurance exercises 
(bicycle, treadmill, walking). The program can start with breathing exercises 
or balance training, continued by aerobic exercise and resistance training. 
Exercises should primarily focus on increasing the strength and the muscle 
mass of the lower limbs and diaphragm. The interval technique can also be 
used, allowing the patient to rest between exercises. In patients who experi-
ence desaturations (SpO2 < 85%) during training, oxygen supplementation 
should be considered in order to maintain SpO2 above 88% [21]. During a 
program of 2–3 sessions/week, for 4–6 weeks, under the supervision of a 
physiotherapist, a patient can learn and become adequately trained to pass 
into the second phase.
• In the continuation and improvement phase, subjects can progressively 
increase both the frequency (3–4 times/week), duration, and intensity of 
the sessions. The aerobic program can be extended to 20–50 min and can be 
performed at an intensity of 60–85% of the work peak rate. The resistance 
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training can last between 20 and 30 min, with an intensity of 80–100% from 
the average walking speed obtained in the 6MWD test. Also, the programs 
recommend including 10–15 min of stretching and a minimum of 5 min of 
diaphragmatic or pursed lip breathing [90].
• The maintenance phase is important for preserving the benefits of a PRP, for 
decreasing the anxiety and depression level, and for increasing the quality of 
life. It is recommended to maintain the types and the intensity of exercises that 
will lead to a level of fatigue between 5 and 7 on the Borg scale.
Each patient should be reassessed at 3–6 months, in terms of effort tolerance, 
quality of life, disease progression, and response to pharmacological treatment.
In brief, a supervised training program for patients with IPF should recommend:
• 4–6 weeks, 2–3 sessions/week
• Aerobic effort 20–40 min
• Stretching 10–15 min
• Breathing techniques 5–10 min
• Adjusting the work intensity so it can be tolerable for the patient
• Oxygen supplementation for patients who desaturate (SpO2 85–88%)
• Intervals between exercises allowing better oxygenation
• Patient reassessment at the end of the 6 weeks
In a comprehensive PRP, patient’s education begins from understanding the 
patient’s needs and providing detailed information regarding the nature and 
expected course of the disease, solutions for symptoms management, benefits and 
side effects of treatments (depression, anxiety, obesity, diabetes, cardiovascular 
disease), the indication of oxygen supplementation, energy conservation tech-
niques, relaxation and recreation methods, stress management, coping techniques 
for anxiety and depression, smoking cessation, and solutions for the improvement 
of quality of life. Medical education sessions usually precede exercise training 
sessions. This will be individualized for each patient, ensuring optimal commu-
nication between the patient and the multidisciplinary team. Educational assess-
ment begins with the identification of difficulties, focusing on the change of the 
health-related behavior. Goals need to be established in the short, medium, and 
long term, to increase the patient’s motivation to follow a PRP. Educational therapy 
plays a role in the relief of symptoms and quality of life improvement, optimizing 
the benefits of a PRP [11].
Nutritional support refers to weight control and a balanced diet, with obesity or 
weight loss being associated with a poor prognosis. Adipose mass can be evaluated 
pre- and post-PR, using different skinfold calipers for the analysis of body composi-
tion by skinfold thickness measurements [91].
Due to the life-threatening course of the disease, the psychological support 
should be considered for each patient. The dialog among the patient, the patient’s 
family, and healthcare professionals can decrease the depression and anxiety in 
more than 50% of ILD patients [56].
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8. Results of the exercise training programs
Studies conducted support the beneficial effects of PR programs, at the end of 
which patients with IPF present [15, 19, 33]:
• Improvement in functional capacity
• Improvement in 6MWD results over SMD: 35.63 m (95% CI 16.02–55.23 m)
• Improvement in V′O2 peak at 6WMD 1.46 mL/kg/min
−1 (95% CI 
0.54–2.39 mL/kg/min−1)
• Increased physical activity levels (IPAQ )
• Significant reduction in dyspnea: SMD −0.68 (95% CI −1.12 to −0.25)
• Improvement in wellness and health-related quality of life, especially for those 
with severe disease SMD 0.59 (95% CI 0.14–1.03)
• Increased muscular fitness
Quality of the evidence regarding the impact of PR programs in IPF patients 
after Dowman et al. [15]:
1. Change in 6-min walk distance—moderate ⊕⊕⊕⊝
2. Change in V′O2 peak uptake at cardiopulmonary exercise test—low ⊕⊕⊝⊝
3. Change in maximum ventilation cardiopulmonary exercise test—low ⊕⊕⊝⊝
4. Change in dyspnea score MMRC Dyspnea Scale—low ⊕⊕⊝⊝
5. Change in quality of life CRDQ (total score)—low ⊕⊕⊝⊝
6. Month survival—low ⊕⊕⊝⊝
A follow-up was performed 8–12 weeks after end of rehabilitation.
The review used the Grades of Recommendation, Assessment, Development 
and Evaluation (GRADE) to evaluate the study results: “Moderate quality: Further 
research is likely to have an important impact on our confidence in the estimate of 
effect and may change the estimate. Low quality: Further research is very likely to 
have an important impact on our confidence in the estimate of effect and is likely to 
change the estimate” [15].
The increase in effort capacity is directly related to training frequency, three to 
five sessions per week being optimal and fewer than two sessions being unlikely to 
produce meaningful change [92].
It is considered that a PR has been beneficial if there has been an increase of 
more than 50 m at 6MWD test (31–81 m gained in PR in different clinical trials) and 
a minimum amount of physical activity at 200 METS-min/week [10 min × 4METS 
(moderate intensity in the IPAQ questionnaire) × 5 times/week. Longer programs 
and more frequent sessions (12 or more) appear to have a greater benefit; however 
these benefits can be lost after 3–6 months, if the training does not continue and 
patients fail to maintain an active lifestyle [11]. There are discrepancies in the 
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outcome of the studies, in patients who have undergone a pulmonary rehabilitation 
program, discussing the responder or non-responder label depending on whether 
or not the walking distance of 6MWD or V′O2 has improved. Non-responders are 
considered patients whose result of 6MWT did not rise above or equal to 30 m after 
PR (30 m considered as MCID) [93]. Also, the responders had FEV1 and TLC raised 
after the rehabilitation program and significantly increased V′O2 peak, carbon diox-
ide output (VCO2), and minute ventilation (VE) in the 6MWT post-PR test, while 
non-responders showed greater desaturation during exercise [93].
The different results of the studies can be explained by:
• Training programs with differences in intensity, duration, and type of admin-
istration (inpatient/outpatient, supervised/unsupervised)
• Small numbers of participants
• Methodological limitation: methods of randomization (uncontrolled studies or 
nonrandomized, unblinded study)
• Limitations of retrospective studies
• Different control batches (other types of ILD, sham, etc.)
• Patients entering PR at different stages of severity
• Inclusion and exclusion criteria
• No follow-up data after exercise training
• Different outcomes
9. Lung transplant pre- and post-rehabilitation programs
Conforming to the International Society for Heart and Lung Transplantation 
(ISHLT), this pulmonary transplantation is performed for a variety of advanced 
lung diseases, IPF, together with COPD, being the most common indication. 
However, in posttransplant survival, IPF is associated with the worst prognosis. For 
patients with IPF, transplantation and supplemental oxygen were the only treat-
ments strongly recommended by the latest ATS consensus document. A transplant 
discussion is recommended from the moment the positive diagnosis is confirmed 
due to low survival [94, 95].
Medical and surgical interventions in transplants have progressed in the last 
few years. All of these lead to a changing demographic of patients undergoing lung 
transplantation, including older subjects with multiple comorbidities, respiratory 
failure, and even those who require bridging to transplantation [95]. To ensure a 
high rate of posttransplant survival, both in the short and long term, these patients 
must be physically and psychologically trained for this complex process. PRP 
plays an essential role in pulmonary transplantation, both by optimizing physical 
function prior to surgical intervention and by facilitating posttransplant recovery. 
Although these PRP are mandatory in most transplant centers, to date there is no 
international pulmonary rehabilitation guideline for this patient category [95].
Physiotherapists working with lung transplant candidates and recipients need 
expertise both in general exercise training principles and in pre- and posttransplant 
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rehabilitation, complications, oxygen titration, and side effects of medications. 
They should be able to adapt exercise programs according to the lung function 
changes and according to episodic illnesses (exacerbation) [95, 96].
Prior to transplant, patients should attend PRP and benefit from exercise 
training, aerobic, resistance, and flexibility, with or without oxygen support, in the 
tolerance limit. In early posttransplant period, mobility is advised even in ICU and 
in acute hospitalization, for the progression to independent function (transfers, 
walking, self-care, climbing stairs). In the next phase (1–6 month), they should 
gradually perform balance training, aerobic, resistance, and flexibility exercises, 
as tolerated. Oxygen can be supplemented to support exercise. In the long term 
(>6 months), patients should be included in home and community PR programs for 
maintaining and improving the benefits of this intervention [96]. All these aspects 
are the premises for a better prognosis and lower costs for the healthcare system.
10. General recommendations
• A multidisciplinary team that includes a respiratory specialist and a clinical 
psychotherapist should manage and supervise the inclusion in a PR program 
of patients with IPF and the structure and monitoring of the patients’ exercise 
training sessions.
• In patients with severe IPF, it is preferred that programs are held in the hospi-
tal. In case programs are held at patient’s home, then high-intensity exercises 
that could lead to desaturation and worsening of symptoms should be avoided.
• For long-term benefits, three to five sessions per week for a minimum of 
6 weeks are optimal, less than two sessions being unlikely to produce signifi-
cant change [92].
• Initially, the interval training method is preferred, and in time, the duration of 
the exercises can be increased. A break and rest are mandatory when excessive 
fatigue and dyspnea appear [12].
• The overall load increases gradually according to patient’s tolerance, the 
intensity of effort being adjusted to patients’ fatigue tolerance.
• Additional oxygen can be used during exercise as it allows for an increased 
endurance and intensity of exercise levels [1].
• Factors such as self-motivation, fear of adverse events, or comprehension may 
affect the ability to tolerate exercise training.
11. Conclusions
The pulmonary rehabilitation has become a clear indication as a non-phar-
macological therapy for patients diagnosed with IPF. The benefits of pulmonary 
rehabilitation programs are reduced respiratory symptoms, especially dyspnea, and 
increased exercise tolerance and level of physical activity. All these lead to a lower 
level of anxiety and depression and therefore increased quality of life. These ben-
efits are sustained in short term, 3–6 months. They can be maintained for a longer 
period if the patient has a responsible behavior and an active lifestyle.
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